C.M. Kurbacher

Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial

Volker Möbus, Michael Untch, Andreas du Bois et al. · Journal of Clinical Oncology · 2004 · 74 citations

Medicine, Oncology, Pharmacology +11

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

Volker Moebus, C. Jackisch, J. Huober et al. · JNCI Journal of the National Cancer Institute · 2013 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Breast Cancer Treatment with Everolimus and Exemestane for Er+ Women - Results of the 2Nd Interim Analysis of the Non-Interventional Trial Brawo

Peter A. Fasching, Thomas Decker, Christoph Uleer et al. · Annals of Oncology · 2014 · 19 citations

Medicine, Oncology, Surgery +16

Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC)

U. Michael, Christian Jackisch, M Lenhard et al. · Journal of Clinical Oncology · 2005 · 16 citations

Medicine, Oncology, Pharmacology +13

Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients

Thomas Schöndorf, Heike Engel, C.M. Kurbacher et al. · Journal of the Society for Gynecologic Investigation · 1998 · 14 citations

Medicine, Immunology, Oncology +17